Management of Vestibular Neuritis
Vestibular rehabilitation therapy (VRT) should be the primary treatment for vestibular neuritis, with corticosteroids added for enhanced early recovery when not contraindicated.
Acute Phase Management
Vestibular Rehabilitation Therapy (Primary Treatment)
- VRT is the cornerstone of treatment and should be initiated early after diagnosis 1, 2
- Early VRT combined with standard care significantly reduces perceived dizziness at 3 months (p = 0.007) and 12 months (p = 0.001) compared to standard care alone 2
- VRT improves subjective outcomes (Dizziness Handicap Inventory scores) earlier than corticosteroids alone, with significant differences at 1 month follow-up 3
- The rehabilitation program should be supervised, individually tailored, and supported by home exercises 2
Corticosteroid Therapy (Adjunctive)
- Corticosteroids enhance earlier objective recovery (canal paresis improvement) but do not provide long-term advantages over VRT alone 3
- A 10-day course of prednisolone is the standard regimen when corticosteroids are used 2
- Corticosteroids show improved caloric recovery (risk ratio 2.81,95% CI 1.32 to 6.00) but uncertain clinical benefit for patient-reported symptoms 4
- The evidence for corticosteroids alone is limited, with very low certainty for clinically meaningful outcomes like dizziness disability 4
Combined Therapy (Optimal Approach)
- The combination of VRT plus corticosteroids is superior to either treatment alone 1, 3
- Combined therapy shows significant improvement in Dizziness Handicap Inventory scores at 1 month (mean difference: -14.86), 3 months (pooled mean difference: -4.63), and 12 months (mean difference: -9.50) compared to steroids alone 1
- Combined therapy improves caloric lateralization at 1 month (pooled mean difference: -10.28) and 3 months (pooled mean difference: -8.12) compared to steroids alone 1
- Vestibular-evoked myogenic potentials show better recovery with combination therapy at 1 month (risk ratio: 0.66) and 3 months (risk ratio: 0.60) 1
Medications to Avoid
- Do not routinely prescribe vestibular suppressant medications such as antihistamines or benzodiazepines 5
- These medications are ineffective for vestibular neuritis and carry risks of adverse effects, medication interactions, and decreased diagnostic sensitivity 5
- A very small subset of severely symptomatic patients refusing other treatments may require temporary vestibular suppression until definitive treatment can be initiated 5
Follow-up and Monitoring
- Reassess patients within 1 month after initial treatment to document symptom resolution or persistence 5
- Long-term outcomes (12 months) show no significant differences between VRT, corticosteroids, or combination therapy, indicating all approaches eventually lead to similar recovery 3
- Patients may develop residual or permanent inner ear balance loss requiring long-term vestibular therapy for compensation 5
Clinical Pearls and Pitfalls
Common Pitfalls to Avoid:
- Relying solely on corticosteroids without VRT—this misses the superior subjective symptom improvement that VRT provides 3
- Delaying VRT initiation—early intervention produces better outcomes 2
- Using vestibular suppressants routinely—these are generally contraindicated and delay recovery 5
Patient Selection Considerations:
- VRT referral rates do not vary by sex, race, or insurance status, and most referred patients demonstrate vestibular dysfunction on baseline assessments 6
- Approximately 68.8% of referred patients actually initiate VRT, highlighting the importance of patient education and engagement 6
- Patients with public insurance may have more severe baseline dysfunction (abnormal Dynamic Gait Index and slower gait speeds), potentially indicating delayed presentation 6